子宫内膜异位症诊断标志物的研究进展

doi:10.12280/gjfckx.20201115

摘要/Abstract

摘要：

子宫内膜异位症（endometriosis,EMs）是一种好发于育龄期女性,具有恶性潜能的良性疾病,发病率约为10%。因该疾病起病隐匿,且只能通过腹腔镜和组织病理学等有创操作进行确诊,目前临床诊断上缺少敏感而特异的生物学指标,导致疾病的诊断及治疗延迟,严重影响女性的生活质量。因此,寻找无创的生物标志物对EMs的临床的诊断和治疗具有重大意义。研究发现患有EMs女性的血清、尿液及月经血等体液中存在一些诊断标志物,使用这些标志物诊断具有简便、快速且无创等优势,成为该病诊断的一个重要方向。

关键词: 子宫内膜异位症, 生物标记, 诊断, 组蛋白类, E盒结合锌指蛋白1, 基质金属蛋白酶2, 基质金属蛋白酶9, 半乳糖凝集素类, HMGB1蛋白质

Abstract:

Endometriosis (EMs) is a benign disease with high malignant potential in women of childbearing age, with a incidence rate of 10%. Because the onset of the disease is hidden, and can only be diagnosed by laparoscopy and histopathology and other invasive operations, the lack of sensitive and specific biological indicators in clinical diagnosis leads to the delay of diagnosis and treatment of the disease, which seriously affects the quality of life of women. Therefore, it is of great significance to find non-invasive biomarkers for clinical diagnosis and treatment of EMs. Studies have found that there are some diagnostic markers in the serum, urine and menstrual blood of women with EMs. The use of these markers has the advantages of simple, rapid and noninvasive diagnosis, which has become an important direction in the diagnosis of the disease.

Key words: Endometriosis, Biomarkers, Diagnosis, Histones, Zinc finger E-box-binding homeobox 1, Matrix metalloproteinase 2, Matrix metalloproteinase 9, Galectins, HMGB1 protein

孙秀丽, 张广美. 子宫内膜异位症诊断标志物的研究进展[J]. 国际妇产科学杂志, 2021, 48(5): 579-582.

SUN Xiu-li, ZHANG Guang-mei. Research Progress of Diagnostic Markers for Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2021, 48(5): 579-582.

参考文献 35

[1]	Hirsch M, Begum MR, Paniz É, et al. Diagnosis and management of endometriosis: a systematic review of international and national guidelines[J]. BJOG, 2018,125(5):556-564. doi: 10.1111/1471-0528.14838. doi: 10.1111/1471-0528.14838
[2]	Peiris AN, Chaljub E, Medlock D. Endometriosis. JAMA, 2018,320(24):2608. doi: 10.1001/jama.2018.17953. doi: 10.1001/jama.2018.17953 pmid: 30575883
[3]	Zeitvogel A, Baumann R, Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model[J]. Am J Pathol, 2001,159(5):1839-1852. doi: 10.1016/S0002-9440(10)63030-1. doi: 10.1016/S0002-9440(10)63030-1 pmid: 11696444
[4]	Ahn SH, Singh V, Tayade C. Biomarkers in endometriosis: challenges and opportunities[J]. Fertil Steril, 2017,107(3):523-532. doi: 10.1016/j.fertnstert.2017.01.009. doi: 10.1016/j.fertnstert.2017.01.009
[5]	Surrey ES, Soliman AM, Yang H, et al. Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis[J]. Adv Ther, 2017,34(11):2436-2451. doi: 10.1007/s12325-017-0619-3. doi: 10.1007/s12325-017-0619-3 pmid: 29039055
[6]	Warren LA, Shih A, Renteira SM, et al. Analysis of menstrual effluent: diagnostic potential for endometriosis[J]. Mol Med, 2018,24(1):1. doi: 10.1186/s10020-018-0009-6. doi: 10.1186/s10020-018-0009-6 pmid: 30134794
[7]	Guo SW. Epigenetics of endometriosis[J]. Mol Hum Reprod, 2009,15(10):587-607. doi: 10.1093/molehr/gap064. doi: 10.1093/molehr/gap064
[8]	沈芳华, 吕弘道, 王利明, 等. 子宫内膜异位症患者月经血中PR-B基因甲基化状态无创检测[J]. 中国计划生育学杂志, 2020,28(10):1639-1642,1724. doi: 10.3969/j.issn.1004-8189.2020.10.031. doi: 10.3969/j.issn.1004-8189.2020.10.031
[9]	Mylonas I, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium[J]. Acta Histochem, 2004,106(3):245-252. doi: 10.1016/j.acthis.2004.02.005. doi: 10.1016/j.acthis.2004.02.005
[10]	宁辉, 刘培淑, 朱彬. 卵巢子宫内膜异位症异位和在位内膜组织中孕激素受体亚型的表达及意义[J]. 中国实用妇科与产科杂志, 2006,22(10):756-758. doi: 10.3969/j.issn.1005-2216.2006.10.015. doi: 10.3969/j.issn.1005-2216.2006.10.015
[11]	Wheatley SP Altieri DC. Survivin at a glance[J]. J Cell Sci, 2019, 132(7):jcs223826. doi: 10.1242/jcs.223826. doi: 10.1242/jcs.223826
[12]	Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis[J]. Int Rev Cytol, 2005,247:35-88. doi: 10.1016/S0074-7696(05)47002-3. doi: 10.1016/S0074-7696(05)47002-3 pmid: 16344111
[13]	Vetvicka V, Laganà AS, Salmeri FM, et al. Regulation of apoptotic pathways during endometriosis: from the molecular basis to the future perspectives[J]. Arch Gynecol Obstet, 2016,294(5):897-904. doi: 10.1007/s00404-016-4195-6. doi: 10.1007/s00404-016-4195-6 pmid: 27628753
[14]	Filipchiuk C, Laganà AS, Beteli R, et al. BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis[J]. Diagnostics (Basel), 2020,10(8):533. doi: 10.3390/diagnostics10080533. doi: 10.3390/diagnostics10080533
[15]	Acimovic M, Vidakovic S, Milic N, et al. Survivin and VEGF as Novel Biomarkers in Diagnosis of Endometriosis[J]. J Med Biochem, 2016,35(1):63-68. doi: 10.1515/jomb-2015-0005. doi: 10.1515/jomb-2015-0005 pmid: 28356866
[16]	Chen R, Kang R, Fan XG, et al. Release and activity of histone in diseases[J]. Cell Death Dis, 2014,5(8):e1370. doi: 10.1038/cddis.2014.337. doi: 10.1038/cddis.2014.337
[17]	凌丽, 熊正爱. 子宫内膜异位症免疫机制研究进展[J]. 国际妇产科学杂志, 2015,42(1):33-37. doi: 10.3969/j.issn.1674-1870.2015.01.009. doi: 10.3969/j.issn.1674-1870.2015.01.009
[18]	Chen X, Liu H, Sun W, et al. Elevated urine histone 4 levels in women with ovarian endometriosis revealed by discovery and parallel reaction monitoring proteomics[J]. J Proteomics, 2019,204:103398. doi: 10.1016/j.jprot.2019.103398. doi: S1874-3919(19)30170-8 pmid: 31146047
[19]	Krebs AM, Mitschke J, Lasierra Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer[J]. Nat Cell Biol, 2017,19(5):518-529. doi: 10.1038/ncb3513. doi: 10.1038/ncb3513
[20]	Caramel J, Ligier M, Puisieux A. Pleiotropic Roles for ZEB1 in Cancer[J]. Cancer Res, 2018,78(1):30-35. doi: 10.1158/0008-5472.CAN-17-2476. doi: 10.1158/0008-5472.CAN-17-2476 pmid: 29254997
[21]	Zhang Y, Xu L, Li A, et al. The roles of ZEB1 in tumorigenic progression and epigenetic modifications[J]. Biomed Pharmacother, 2019,110:400-408. doi: 10.1016/j.biopha.2018.11.112. doi: S0753-3322(18)36204-8 pmid: 30530042
[22]	Wu RF, Chen ZX, Zhou WD, et al. High expression of ZEB1 in endometriosis and its role in 17β-estradiol-induced epithelial-mesenchymal transition[J]. Int J Clin Exp Pathol, 2018,11(10):4744-4758.
[23]	李欢欢, 张旭艳, 汤孟冬, 等. PI3K和MMP-9在子宫内膜异位症中的表达及意义[J]. 潍坊医学院学报, 2020,42(2):118-120. doi: 10.16846/j.issn.1004-3101.2020.02.011. doi: 10.16846/j.issn.1004-3101.2020.02.011
[24]	Barbe AM, Berbets AM, Davydenko IS, et al. Expression and Significance of Matrix Metalloproteinase-2 and Matrix Metalloproteinas-9 in Endometriosis[J]. J Med Life, 2020,13(3):314-320. doi: 10.25122/jml-2020-0117. doi: 10.25122/jml-2020-0117
[25]	李灿宇, 王停停, 刘欢欢, 等. VEGF、MMP-9、Galectin-3在卵巢子宫内膜异位症发病中的作用及临床应用价值[J]. 中国医学创新, 2019,16(35):113-117. doi: 10.3969/j.issn.1674-4985.2019.35.027. doi: 10.3969/j.issn.1674-4985.2019.35.027
[26]	Pergialiotis V, Papoutsi E, Androutsou A, et al. Galectins-1, -3, -7, -8 and -9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta-analysis[J]. Int J Gynaecol Obstet, 2020,152(3):299-307. doi: 10.1002/ijgo.13471. doi: 10.1002/ijgo.13471
[27]	Chou FC, Chen HY, Kuo CC, et al. Role of Galectins in Tumors and in Clinical Immunotherapy[J]. Int J Mol Sci, 2018,19(2):430. doi: 10.3390/ijms19020430. doi: 10.3390/ijms19020430
[28]	张小菜, 裴巧丽, 袁宁霞, 等. 可溶性半乳糖凝集素9在子宫内膜异位症中的表达及诊断价值[J]. 中国妇幼保健, 2019,34(9):1988-1991. doi: 10.7620/zgfybj.j.issn.1001-4411.2019.09.15. doi: 10.7620/zgfybj.j.issn.1001-4411.2019.09.15
[29]	Hisrich BV, Young RB, Sansone AM, et al. Role of Human Galectins in Inflammation and Cancers Associated with Endometriosis[J]. Biomolecules, 2020,10(2):230. doi: 10.3390/biom10020230. doi: 10.3390/biom10020230
[30]	姜雪, 张宗峰. 免疫功能障碍与子宫内膜异位症发生发展的研究现状[J]. 国际妇产科学杂志, 2019,46(5):532-535. doi: 10.3969/j.issn.1674-1870.2019.05.013. doi: 10.3969/j.issn.1674-1870.2019.05.013
[31]	朱晓芳, 张海燕, 何丽, 等. 抗心磷脂抗体及抗子宫内膜抗体与复发性流产的关系探讨[J]. 重庆医学, 2018,47(2):249-251. doi: 10.3969/j.issn.1671-8348.2018.02.035. doi: 10.3969/j.issn.1671-8348.2018.02.035
[32]	王鑫丹, 郑萍. 子宫内膜异位症的免疫机制研究进展[J]. 国际妇产科学杂志, 2019,46(5):536-540.doi: 10.3969/j.issn.1674-1870.2019.05.014. doi: 10.3969/j.issn.1674-1870.2019.05.014
[33]	吴锦杰, 梁炎春, 姚书忠. HMGB1对子宫内膜异位症新生血管生成的潜在作用[J]. 国际妇产科学杂志, 2016,43(2):194-198. doi: 10.3969/j.issn.1674-1870.2016.02.019. doi: 10.3969/j.issn.1674-1870.2016.02.019
[34]	Wang Y, Wang Y, Zhang Z. Adipokine RBP4 drives ovarian cancer cell migration[J]. J Ovarian Res, 2018,11(1):29. doi: 10.1186/s13048-018-0397-9. doi: 10.1186/s13048-018-0397-9
[35]	张洪江, 金春花, 姜春善, 等. 血清抗子宫内膜抗体、HMGB1与视黄醇结合蛋白4在子宫内膜异位症中的表达及意义[J]. 广东医学, 2019,40(14):2054-2057. doi: 10.13820/j.cnki.gdyx.20185170. doi: 10.13820/j.cnki.gdyx.20185170